The clinical-stage private company, which merged with Stellar Biotechnologies in 2019, is focused on developing safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Their lead asset, EB01, is a non-steroidal anti-inflammatory molecule that has already shown statistically significant improvements in multiple clinical studies for the treatment of allergic contact dermatitis. Edesa Biotech is also exploring novel ways to treat inflammatory and immune-related diseases, including monoclonal antibody therapy for hospitalized COVID-19 patients with their EB05 candidate.